(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

NAVINOVA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

NAVINOVA

ST13

US500000079308794

Class

5

Filing

79308794

Registration

6841307

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

36

Latest update

01/03/2023

Classification

Registered

Trademark type

Combined

Nice classes

5

Filing date

12/21/2020

Registration date

09/13/2022

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

09/13/2022

Last transaction

09/13/2022

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

5

Owner type

99

Owner location

IN

Examiner

SEVERSON, JUSTIN

Law office

M20

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the term "NAVINOVA" in stylized orange font.

Holders and representatives

Holders

NAVIN FLUORINE INTERNATIONAL LIMITED

Representatives

Alexander Lazouski LAZOUSKI IP LLC

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Chemical preparations used in the manufacture of medicinal productsfor the treatment of central nervous system diseasescancermetabolic diseasesendocrine diseasescardiovascular diseaseimmune system related diseases and disordersinfectious diseaseskidney diseasesliver diseasesgastrointestinal diseasesinflammatory diseasesoncologic disordersskin diseases and disordersrespiratory diseasesallergic diseasesneurological disorderspain and psychiatric disorder; chemical preparations for pharmaceuticals purposesfor the treatment of central nervous system diseasescancermetabolic diseasesendocrine diseasescardiovascular diseaseimmune system related diseases and disordersinfectious diseaseskidney diseasesliver diseasesgastrointestinal diseasesinflammatory diseasesoncologic disordersskin diseases and disordersrespiratory diseasesallergic diseasesneurological disorderspain and psychiatric disorder chemical preparations for medical purposesdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; chemical preparations for pharmaceuticals purposes for the treatment of central nervous system diseasescancermetabolic diseasesendocrine diseasescardiovascular diseaseimmune system related diseases and disordersinfectious diseaseskidney diseasesliver diseasesgastrointestinal diseasesinflammatory diseasesoncologic disordersskin diseases and disordersrespiratory diseasesallergic diseasesneurological disorderspain and psychiatric disorder; medicinal and pharmaceutical preparations for the treatment of central nervous system diseasescancermetabolic diseasesendocrine diseasescardiovascular diseaseimmune system related diseases and disordersinfectious diseaseskidney diseasesliver diseasesgastrointestinal diseasesinflammatory diseasesoncologic disordersskin diseases and disordersrespiratory diseasesallergic diseasesneurological disorderspain and psychiatric disorder; chemical preparations for veterinary purposes for the treatment of central nervous system diseasescancermetabolic diseasesendocrine diseasescardiovascular diseaseimmune system related diseases and disordersinfectious diseaseskidney diseasesliver diseasesgastrointestinal diseasesinflammatory diseasesoncologic disordersskin diseases and disordersrespiratory diseasesallergic diseasesneurological disorderspain and psychiatric disorder; disinfectants; insecticides; germicides; pesticides; preparations for fungicidesherbicides and preparations for destroying vermin

Publications

History of USPTO decisions and trademark events.

36 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/03/2023

FICS

FINAL DISPOSITION NOTICE SENT TO IB

12/14/2022

FIMP

FINAL DISPOSITION PROCESSED

12/14/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

12/13/2022

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

09/13/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

09/13/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

06/28/2022

PUBO

PUBLISHED FOR OPPOSITION

06/28/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

06/08/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/18/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

05/18/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

05/18/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

05/18/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

05/18/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/13/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/13/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/13/2022

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/27/2022

GNRT

NON-FINAL ACTION E-MAILED

01/27/2022

CNRT

NON-FINAL ACTION WRITTEN

01/27/2022

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

01/11/2022

PBCR

WITHDRAWN FROM PUB - OG REVIEW QUERY

12/21/2021

ALIE

ASSIGNED TO LIE

12/09/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/08/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/06/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/06/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/06/2021

RFNT

REFUSAL PROCESSED BY IB

07/19/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

07/01/2021

RFRR

REFUSAL PROCESSED BY MPU

07/01/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

06/22/2021

CNRT

NON-FINAL ACTION WRITTEN

06/21/2021

DOCK

ASSIGNED TO EXAMINER

06/16/2021

MAFR

APPLICATION FILING RECEIPT MAILED

04/24/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/20/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/15/2021

Continuous trademark protection

Get notified about every new filing that threatens NAVINOVA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.